Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2014 | Pages:
249 | Publisher: Global Markets Direct
Industry: Healthcare | Report Format: Electronic (PDF)
Hemorrhagic Fever - Pipeline Review, H2 2014 Summary Global Markets Direct's, 'Hemorrhagic Fever - Pipeline Review, H2 2014', provides an overview of the Hemorrhagic Fever's therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Hemorrhagic Fever, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hemorrhagic Fever and special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Hemorrhagic Fever - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Hemorrhagic Fever and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Hemorrhagic Fever products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Hemorrhagic Fever pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hemorrhagic Fever - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hemorrhagic Fever pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents Table of Contents 2 List of Tables 7 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Hemorrhagic Fever Overview 10 Therapeutics Development 11 Pipeline Products for Hemorrhagic Fever - Overview 11 Pipeline Products for Hemorrhagic Fever - Comparative Analysis 12 Hemorrhagic Fever - Therapeutics under Development by Companies 13 Hemorrhagic Fever - Therapeutics under Investigation by Universities/Institutes 18 Hemorrhagic Fever - Pipeline Products Glance 20 Late Stage Products 20 Clinical Stage Products 21 Early Stage Products 22 Unknown Stage Products 23 Hemorrhagic Fever - Products under Development by Companies 24 Hemorrhagic Fever - Products under Investigation by Universities/Institutes 29 Hemorrhagic Fever - Companies Involved in Therapeutics Development 30 Adamas Pharmaceuticals, Inc. 30 AlphaVax, Inc. 31 Arbovax, Inc. 32 BioCryst Pharmaceuticals, Inc. 33 Chimerix, Inc. 34 Crucell N.V. 35 Epirus Biopharmaceuticals, Inc. 36 Evolva SA 37 FIT Biotech Oyj 38 GeoVax Labs, Inc. 39 GlaxoSmithKline plc 40 Hawaii Biotech, Inc. 41 Hemispherx Biopharma, Inc. 42 Humabs BioMed SA 43 iBio, Inc. 44 Immunovaccine, Inc. 45 Inovio Pharmaceuticals, Inc. 46 Integrated BioTherapeutics, Inc. 47 Janssen Pharmaceuticals, Inc. 48 Medicago Inc. 49 Microbiotix, Inc. 50 Myelo Therapeutics GmbH 51 NanoViricides, Inc. 52 Navigen Pharmaceuticals, Inc. 53 NewLink Genetics Corporation 54 Novavax, Inc. 55 Panacea Biotec Limited 56 Peregrine Pharmaceuticals, Inc. 57 Profectus BioSciences, Inc. 58 Sarepta Therapeutics, Inc. 59 SIGA Technologies, Inc. 60 Sihuan Pharmaceutical Holdings Group Ltd. 61 SKAU Vaccines ApS 62 Summit Corporation plc 63 Tekmira Pharmaceuticals Corp. 64 Themis Bioscience GmbH 65 Toyama Chemical Co., Ltd. 66 Vaxart, Inc. 67 Hemorrhagic Fever - Therapeutics Assessment 68 Assessment by Monotherapy Products 68 Assessment by Combination Products 69 Assessment by Target 70 Assessment by Mechanism of Action 72 Assessment by Route of Administration 74 Assessment by Molecule Type 76 Drug Profiles 78 1-E703 - Drug Profile 78 ADS-324 - Drug Profile 79 ANSX-109 - Drug Profile 80 ANSX-142 - Drug Profile 81 Antibodies for Crimean Congo Hemorrhagic Fever - Drug Profile 82 ARD-5 - Drug Profile 83 AVI-7012 - Drug Profile 84 AVI-7288 - Drug Profile 85 bavituximab - Drug Profile 86 BCX-4430 - Drug Profile 91 BG-323 - Drug Profile 93 BPSC-1001 - Drug Profile 94 brincidofovir - Drug Profile 95 crimean-congo hemorrhagic fever vaccine - Drug Profile 97 DEF-201 - Drug Profile 98 dengue virus vaccine (tetravalent) - Drug Profile 100 DengueCide - Drug Profile 101 DiTU - Drug Profile 102 DNA Vaccines - Drug Profile 103 Drugs for Ebola and Marburg Infections - Drug Profile 104 ebola (virus like particles) vaccine - Drug Profile 105 ebola and marburg vaccine (trivalent) - Drug Profile 106 Ebola Vaccine - Drug Profile 108 ebola vaccine - Drug Profile 110 ebola vaccine - Drug Profile 111 Ebola Vaccine - Drug Profile 112 ebola vaccine - Drug Profile 113 ebola vaccine - Drug Profile 114 ebola vaccine - Drug Profile 115 ebola vaccine - Drug Profile 116 ebola vaccine - Drug Profile 117 ebola vaccine - Drug Profile 118 ebola vaccine - Drug Profile 119 ebola vaccine + marburg vaccine - Drug Profile 121 ebola vaccine [zaire] - Drug Profile 122 ebola virus vaccine - Drug Profile 123 EMER-IT - Drug Profile 124 ET-007 - Drug Profile 125 ETX-101 - Drug Profile 126 EV-075 - Drug Profile 127 favipiravir - Drug Profile 128 Filovirus Vaccine - Drug Profile 130 GOVXE-301 - Drug Profile 131 GOVXE-302 - Drug Profile 132 GreEMTri - Drug Profile 133 hemorrhagic fever (bivalent) vaccine - Drug Profile 134 imatinib mesylate - Drug Profile 135 INO-4200 - Drug Profile 136 interferon alfa-n3 - Drug Profile 137 JK-05 - Drug Profile 138 lassa fever vaccine - Drug Profile 139 lassa fever vaccine 1 - Drug Profile 140 lassa fever vaccine 2 - Drug Profile 141 LCTA-949 - Drug Profile 142 marburg vaccine - Drug Profile 143 marburg vaccine - Drug Profile 144 marburg virus vaccine - Drug Profile 145 MMCatLMC - Drug Profile 146 Monoclonal Antibodies for Ebola and Marburg Infections - Drug Profile 147 Monoclonal Antibodies for Rift Valley Fever - Drug Profile 148 Monoclonal Antibodies for Viral Infections - Drug Profile 149 Monoclonal Antibodies to Inhibit Glycoprotein for Marburg Virus Infection - Drug Profile 151 Monoclonal Antibody for Ebola Virus Infections - Drug Profile 152 Monoclonal Antibody for Marburg Virus - Drug Profile 153 MVA-BN-Filoviruses Vaccine - Drug Profile 154 Myelo-001 - Drug Profile 155 NoBola - Drug Profile 156 oxocarbazate - Drug Profile 157 panfilovirus (multivalent) vaccine - Drug Profile 158 rintatolimod - Drug Profile 159 Slit2N - Drug Profile 161 Small Molecule for Argentine Hemorrhagic Fever - Drug Profile 163 Small Molecule for Bunya Virus - Drug Profile 164 Small Molecules to Inhibit Cathepsin L for Ebola Virus Infection - Drug Profile 165 Small Molecules to Inhibit Niemann Pick C1 for Ebola Viral Infections - Drug Profile 166 Small Molecules to Inhibit NPC1 for Ebola and Lassa Fever Virus - Drug Profile 167 Small Molecules to Inhibit SAH Hydrolase for Ebola Virus Infection - Drug Profile 168 Small Molecules to Target Estrogen Receptor for Ebola Virus Infection - Drug Profile 169 SMT-15000 - Drug Profile 170 ST-161 - Drug Profile 171 ST-193 - Drug Profile 172 Synthetic Peptides for Ebola Virus - Drug Profile 173 thiocarbazate - Drug Profile 174 TKM-100701 - Drug Profile 175 TKM-100802 - Drug Profile 176 TKM-Marburg - Drug Profile 179 TSI-GSD-200 - Drug Profile 180 yellow fever and arenavirus vaccine - Drug Profile 181 yellow fever vaccine - Drug Profile 182 yellow fever vaccine - Drug Profile 183 yellow fever vaccine - Drug Profile 184 yellow fever vaccine - Drug Profile 185 yellow fever vaccine - Drug Profile 186 yellow fever vaccine - Drug Profile 187 yellow fever vaccine (YF17D) - Drug Profile 188 ZMAb - Drug Profile 189 ZMapp - Drug Profile 190 Hemorrhagic Fever - Recent Pipeline Updates 192 Hemorrhagic Fever - Dormant Projects 231 Hemorrhagic Fever - Discontinued Products 233 Hemorrhagic Fever - Product Development Milestones 234 Featured News & Press Releases 234 Appendix 242 Methodology 242 Coverage 242 Secondary Research 242 Primary Research 242 Expert Panel Validation 242 Contact Us 243 Disclaimer 243
List of Tables Number of Products under Development for Hemorrhagic Fever, H2 2014 17 Number of Products under Development for Hemorrhagic Fever - Comparative Analysis, H2 2014 18 Number of Products under Development by Companies, H2 2014 20 Number of Products under Development by Companies, H2 2014 (Contd..1) 21 Number of Products under Development by Companies, H2 2014 (Contd..2) 22 Number of Products under Development by Companies, H2 2014 (Contd..3) 23 Number of Products under Investigation by Universities/Institutes, H2 2014 25 Comparative Analysis by Late Stage Development, H2 2014 26 Comparative Analysis by Clinical Stage Development, H2 2014 27 Comparative Analysis by Early Stage Development, H2 2014 28 Comparative Analysis by Unknown Stage Development, H2 2014 29 Products under Development by Companies, H2 2014 30 Products under Development by Companies, H2 2014 (Contd..1) 31 Products under Development by Companies, H2 2014 (Contd..2) 32 Products under Development by Companies, H2 2014 (Contd..3) 33 Products under Development by Companies, H2 2014 (Contd..4) 34 Products under Investigation by Universities/Institutes, H2 2014 35 Hemorrhagic Fever - Pipeline by Adamas Pharmaceuticals, Inc., H2 2014 36 Hemorrhagic Fever - Pipeline by AlphaVax, Inc., H2 2014 37 Hemorrhagic Fever - Pipeline by Arbovax, Inc., H2 2014 38 Hemorrhagic Fever - Pipeline by BioCryst Pharmaceuticals, Inc., H2 2014 39 Hemorrhagic Fever - Pipeline by Chimerix, Inc., H2 2014 40 Hemorrhagic Fever - Pipeline by Crucell N.V., H2 2014 41 Hemorrhagic Fever - Pipeline by Epirus Biopharmaceuticals, Inc., H2 2014 42 Hemorrhagic Fever - Pipeline by Evolva SA, H2 2014 43 Hemorrhagic Fever - Pipeline by FIT Biotech Oyj, H2 2014 44 Hemorrhagic Fever - Pipeline by GeoVax Labs, Inc., H2 2014 45 Hemorrhagic Fever - Pipeline by GlaxoSmithKline plc, H2 2014 46 Hemorrhagic Fever - Pipeline by Hawaii Biotech, Inc., H2 2014 47 Hemorrhagic Fever - Pipeline by Hemispherx Biopharma, Inc., H2 2014 48 Hemorrhagic Fever - Pipeline by Humabs BioMed SA, H2 2014 49 Hemorrhagic Fever - Pipeline by iBio, Inc., H2 2014 50 Hemorrhagic Fever - Pipeline by Immunovaccine, Inc., H2 2014 51 Hemorrhagic Fever - Pipeline by Inovio Pharmaceuticals, Inc., H2 2014 52 Hemorrhagic Fever - Pipeline by Integrated BioTherapeutics, Inc., H2 2014 53 Hemorrhagic Fever - Pipeline by Janssen Pharmaceuticals, Inc., H2 2014 54 Hemorrhagic Fever - Pipeline by Medicago Inc., H2 2014 55 Hemorrhagic Fever - Pipeline by Microbiotix, Inc., H2 2014 56 Hemorrhagic Fever - Pipeline by Myelo Therapeutics GmbH, H2 2014 57 Hemorrhagic Fever - Pipeline by NanoViricides, Inc., H2 2014 58 Hemorrhagic Fever - Pipeline by Navigen Pharmaceuticals, Inc., H2 2014 59 Hemorrhagic Fever - Pipeline by NewLink Genetics Corporation, H2 2014 60 Hemorrhagic Fever - Pipeline by Novavax, Inc., H2 2014 61 Hemorrhagic Fever - Pipeline by Panacea Biotec Limited, H2 2014 62 Hemorrhagic Fever - Pipeline by Peregrine Pharmaceuticals, Inc., H2 2014 63 Hemorrhagic Fever - Pipeline by Profectus BioSciences, Inc., H2 2014 64 Hemorrhagic Fever - Pipeline by Sarepta Therapeutics, Inc., H2 2014 65 Hemorrhagic Fever - Pipeline by SIGA Technologies, Inc., H2 2014 66 Hemorrhagic Fever - Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H2 2014 67 Hemorrhagic Fever - Pipeline by SKAU Vaccines ApS, H2 2014 68 Hemorrhagic Fever - Pipeline by Summit Corporation plc, H2 2014 69 Hemorrhagic Fever - Pipeline by Tekmira Pharmaceuticals Corp., H2 2014 70 Hemorrhagic Fever - Pipeline by Themis Bioscience GmbH, H2 2014 71 Hemorrhagic Fever - Pipeline by Toyama Chemical Co., Ltd., H2 2014 72 Hemorrhagic Fever - Pipeline by Vaxart, Inc., H2 2014 73 Assessment by Monotherapy Products, H2 2014 74 Assessment by Combination Products, H2 2014 75 Number of Products by Stage and Target, H2 2014 77 Number of Products by Stage and Mechanism of Action, H2 2014 79 Number of Products by Stage and Route of Administration, H2 2014 81 Number of Products by Stage and Molecule Type, H2 2014 83 Hemorrhagic Fever Therapeutics - Recent Pipeline Updates, H2 2014 198 Hemorrhagic Fever - Dormant Projects, H2 2014 237 Hemorrhagic Fever - Discontinued Products, H2 2014 239
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
